We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Intuitive Surgical (ISRG) Down 7.2% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Intuitive Surgical, Inc. (ISRG - Free Report) . Shares have lost about 7.2% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Intuitive Surgical due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.
ISRG Q1 Earnings & Sales Beat Estimates on Procedure Growth
Intuitive Surgical reported first-quarter 2026 adjusted earnings per share of $2.50, which beat the Zacks Consensus Estimate of $2.08 by 20.2%. The bottom line improved 38.1% year over year.
GAAP earnings per share was $2.28 versus $1.92 a year ago.
Revenue Details
Revenues rose 23% from the year-ago quarter to $2.77 billion, which exceeded the Zacks Consensus Estimate by 6.2%. Growth reflected higher global procedure volume and stronger system placements, led by da Vinci 5.
Revenues for this segment climbed 23.3% year over year to $1.69 billion, supported by procedure growth and customer buying patterns, alongside the sharp increase in Ion procedure volume.
Worldwide procedures (da Vinci and Ion combined) increased about 17% versus the first quarter of 2025, with da Vinci procedures up roughly 16% and Ion procedures up about 39%. ISRG’s strong momentum during the quarter reflects broad-based adoption across its platforms, with strength in the United States and Europe and mixed results in parts of Asia.
Systems: ISRG’s Placements Shift Further Toward da Vinci 5
This segment’s revenues totaled $650.7 million, up 24.5% year over year, driven by capital strength. Intuitive Surgical placed 431 da Vinci systems in the quarter, up from 367 a year earlier. The mix continued to move toward the latest da Vinci 5, with 232 placements compared with 147 in the prior-year quarter. The company also placed 52 Ion systems, modestly higher than 49 a year ago, as Ion adoption expanded alongside growing procedure demand.
Intuitive Surgical highlighted leasing as a meaningful part of placements, including usage-based arrangements, while trade-in activity rose as customers upgraded to da Vinci 5. The company ended the quarter with a da Vinci installed base of 11,395 systems, up 12% year over year, while Ion’s installed base rose 22% to 1,041 systems.
Services
Revenues from this segment improved 19% to $433.7 million, tracking the larger installed base and ongoing demand for support and maintenance.
Adjusted gross profit was $1.88 billion, up 25.6% year over year. As a percentage of revenues, the gross margin was 67.8%, up approximately 140 bps from the prior-year quarter’s figure.
Selling, general and administrative expenses totaled $613.3 million, up 8.9% year over year.
Research and development expenses totaled $361.9 million, up 14.6% on a year-over-year basis.
Adjusted operating income totaled $1.08 billion, up 40.3% year over year. As a percentage of revenues, the operating margin was 38.9%, up approximately 480 bps from the prior-year quarter’s figure.
ISRG’s Financial Position
Capital allocation remained active during the quarter. ISRG repurchased 2.3 million shares for $1.1 billion, reducing cash, cash equivalents, and investments to $7.98 billion at quarter-end from $9.03 billion at the end of fiscal 2025.
Management also pointed to continued investments in product and digital capabilities, including scaling da Vinci 5 globally and expanding the broader ecosystem that supports utilization and adoption.
ISRG’s Procedure & Margin Outlook for 2026
Following the quarter, Intuitive Surgical raised its full-year 2026 da Vinci procedure growth outlook to about 13.5-15.5%. The company also expects adjusted gross margin of 67.5% to 68.5% for 2026, a range that includes an estimated tariff impact of about 1% of revenues, and projects adjusted operating expense growth of 11-14%.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in estimates review.
VGM Scores
Currently, Intuitive Surgical has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Intuitive Surgical has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Intuitive Surgical (ISRG) Down 7.2% Since Last Earnings Report?
It has been about a month since the last earnings report for Intuitive Surgical, Inc. (ISRG - Free Report) . Shares have lost about 7.2% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Intuitive Surgical due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.
ISRG Q1 Earnings & Sales Beat Estimates on Procedure Growth
Intuitive Surgical reported first-quarter 2026 adjusted earnings per share of $2.50, which beat the Zacks Consensus Estimate of $2.08 by 20.2%. The bottom line improved 38.1% year over year.
GAAP earnings per share was $2.28 versus $1.92 a year ago.
Revenue Details
Revenues rose 23% from the year-ago quarter to $2.77 billion, which exceeded the Zacks Consensus Estimate by 6.2%. Growth reflected higher global procedure volume and stronger system placements, led by da Vinci 5.
Segmental Details
Instrument & Accessories: ISRG Procedure Growth Lifts High-Margin Recurring Mix
Revenues for this segment climbed 23.3% year over year to $1.69 billion, supported by procedure growth and customer buying patterns, alongside the sharp increase in Ion procedure volume.
Worldwide procedures (da Vinci and Ion combined) increased about 17% versus the first quarter of 2025, with da Vinci procedures up roughly 16% and Ion procedures up about 39%. ISRG’s strong momentum during the quarter reflects broad-based adoption across its platforms, with strength in the United States and Europe and mixed results in parts of Asia.
Systems: ISRG’s Placements Shift Further Toward da Vinci 5
This segment’s revenues totaled $650.7 million, up 24.5% year over year, driven by capital strength. Intuitive Surgical placed 431 da Vinci systems in the quarter, up from 367 a year earlier. The mix continued to move toward the latest da Vinci 5, with 232 placements compared with 147 in the prior-year quarter. The company also placed 52 Ion systems, modestly higher than 49 a year ago, as Ion adoption expanded alongside growing procedure demand.
Intuitive Surgical highlighted leasing as a meaningful part of placements, including usage-based arrangements, while trade-in activity rose as customers upgraded to da Vinci 5. The company ended the quarter with a da Vinci installed base of 11,395 systems, up 12% year over year, while Ion’s installed base rose 22% to 1,041 systems.
Services
Revenues from this segment improved 19% to $433.7 million, tracking the larger installed base and ongoing demand for support and maintenance.
ISRG Margin Profile Improves Despite Tariff Headwinds
Adjusted gross profit was $1.88 billion, up 25.6% year over year. As a percentage of revenues, the gross margin was 67.8%, up approximately 140 bps from the prior-year quarter’s figure.
Selling, general and administrative expenses totaled $613.3 million, up 8.9% year over year.
Research and development expenses totaled $361.9 million, up 14.6% on a year-over-year basis.
Adjusted operating income totaled $1.08 billion, up 40.3% year over year. As a percentage of revenues, the operating margin was 38.9%, up approximately 480 bps from the prior-year quarter’s figure.
ISRG’s Financial Position
Capital allocation remained active during the quarter. ISRG repurchased 2.3 million shares for $1.1 billion, reducing cash, cash equivalents, and investments to $7.98 billion at quarter-end from $9.03 billion at the end of fiscal 2025.
Management also pointed to continued investments in product and digital capabilities, including scaling da Vinci 5 globally and expanding the broader ecosystem that supports utilization and adoption.
ISRG’s Procedure & Margin Outlook for 2026
Following the quarter, Intuitive Surgical raised its full-year 2026 da Vinci procedure growth outlook to about 13.5-15.5%. The company also expects adjusted gross margin of 67.5% to 68.5% for 2026, a range that includes an estimated tariff impact of about 1% of revenues, and projects adjusted operating expense growth of 11-14%.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in estimates review.
VGM Scores
Currently, Intuitive Surgical has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Intuitive Surgical has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.